Does colchicine have an antifibrotic effect on development of interstitial fibrosis in renal allografts of recipients with familial Mediterranean fever?
Colchicine, which has been reported to inhibit fibrosis, has been successfully used to treat fibrotic disorders, such as liver cirrhosis, scleroderma, and idiopathic pulmonary fibrosis. We hypothesized that besides its ability to prevent amyloid deposition, colchicine may prevent the development of interstitial fibrosis (IF) in amyloidosis patients who had undergone renal transplantation. We evaluated the influence of colchicine therapy on the development of IF in 25 patients with systemic amyloidosis secondary to familial Mediterranean fever (group 1). Twenty-five nonamyloidotic patients who did not receive colchicine therapy served as controls (group 2). The incidences of recurrence and development of IF in the first, second, and third years after transplantation were evaluated from follow-up allograft biopsies. Only four patients showed amyloid recurrence in their renal allografts. IF developed in 44% (11/25) of group 1 patients and 80% (20/25) of group 2 patients during the 36 months posttransplantation (P < .01). Development of IF in the first, second, and third years posttransplantation was significantly greater among group 2 recipients than group 1 recipients (P < .01). The overall 1-, 2-, and 3-year graft survival rates for group 1 recipients were 96%, 92%, and 80%, and those for group 2 recipients were 96%, 88%, and 60%, respectively. Our results support the thesis that colchicine therapy may help prevent the development of interstitial fibrosis in renal allografts.
Ozdemir
B H
BH
Department of Pathology, Baskent University, Faculty of Medicine, Ankara, Turkey. handan27@hotmail.com
Ozdemir
F N
FN
Sezer
S
S
Sar
A
A
Haberal
M
M
D028226:Amyloidosis, Familial / Q000601:surgery*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001706:Biopsy; D003078:Colchicine / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000601:surgery*; D005355:Fibrosis / Q000517:prevention & control; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D016030:Kidney Transplantation / Q000473:pathology / Q000502:physiology*; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D003078:Colchicine